A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]

Shire Human Genetic Therapies, Inc.0 sites93 target enrollmentStarted: November 16, 2017Last updated: February 19, 2024

Conditions

Drugs

Trial Snapshot

Phase: Phase 1
Status: Active, not recruiting
Sponsor: Shire Human Genetic Therapies, Inc.
Enrollment: 93

Study Overview Eligibility Criteria Investigators Records & Identifiers Similar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type: Interventional clinical trial of medicinal product

Eligibility Criteria

Sex: All

Inclusion Criteria

•1. Has an understanding, ability, and willingness to fully comply with study procedures and
•restrictions.
•2. Is able to voluntarily provide a signed and dated informed consent form before any study-related procedures are performed.
•3. Is an adult male or female 18 to 85 years of age, inclusive.
•4. In subjects 18-25 years of age or younger, has radiological evidence of epiphyseal closure based on X-ray of left wrist and left hand before randomization.
•5. Has chronic hypoparathyroidism with onset 12 months or more before screening. The diagnosis of hypoparathyroidism is established based on hypocalcemia in the setting of inappropriately low serum PTH levels.
•6. During the Week -3 screening visit, the subject reports by history at least 2 of the following symptoms related to hypoparathyroidism occurring within the 2 weeks before Week -3 visit: muscle cramps, muscle spasms or twitching, tingling, numbness, heaviness in arms or legs, physical fatigue, or slowed or confused thinking (brain fog).
•7. The subject must have a Hypoparathyroidism Symptom Diary (HPT-SD) symptom subscale Sum Score of =10 during the 14-day period immediately prior to the baseline (Week 0) visit (Day -14 to Day -1). In addition, the subject must have at least 4 HPT-SD diaries completed in the first 7 day period and at least 4 HPT-SD diaries completed in second 7 day period. See Appendix 3 for the calculation of the sum score
•8. Must be treated with active vitamin D (calcitriol or alfacalcidol) alone or in conjunction with calcium supplements for at least 4 months prior to the screening visit.
•. The subject must be taking =0.5 µg/day of calcitriol or =1.0 µg/day of alfacalcidol.
•. If the subject is treated with a lower dose of active vitamin D the subject must also be taking calcium supplements of at least 800 mg/day of elemental calcium
•9. Has thyroid-stimulating hormone (TSH) results within normal laboratory limits at screening for all subjects not receiving thyroid hormone replacement therapy. For subjects on thyroid hormone replacement therapy, the thyroid hormone dose must have been stable for at least 4 weeks before screening, and serum TSH level must be within the
•central laboratory normal range. A serum TSH level below the lower limit of the normal range but not undetectable in subjects treated with thyroid hormone may be allowed if there is no anticipated need for a change in thyroid hormone dose during the trial.
•10. Has serum 25-hydroxyvitamin D levels =50 nmol/L (20 ng/mL) and <1.5 times the upper limit of normal (ULN) for the central laboratory normal range.
•11. Has estimated glomerular filtration rate (eGFR) >30 ml/min/1.73m2.
•12. Prior to randomization, is able to perform daily SC self-injections of study medication (or have a designee perform injection) via a multidose injection pen into the thigh.
•13. Willing to use oral active vitamin D and calcium supplements provided for the study unless directed to remain on the supplements used prior to enrollment in the current study by the investigator after consultation with the medical monitor
•14. With regard to female subjects: women who are postmenopausal (12 consecutive months
•of spontaneous amenorrhea and age more than or equal to 51 years) and women who are surgically sterilized can be enrolled. Women of childbearing potential must have a negative pregnancy test at
•randomization and be willing to comply with any applicable contraceptive requirements of the protocol and pregnancy testing for the duration

Exclusion Criteria

•1. History of hypoparathyroidism resulting from a known activating mutation in the CaSR gene or impaired responsiveness to PTH (pseudohypoparathyroidism).
•2. Any disease that might affect calcium metabolism or calcium-phosphate homeostasis other than hypoparathyroidism, such as poorly controlled hyperthyroidism; Paget disease; type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus; severe and chronic cardiac, liver (Child-Pugh score >9) (US FDA, 2003), or renal disease; Cushing syndrome; rheumatoid arthritis; myeloma; active pancreatitis; malnutrition; rickets; recent prolonged immobility; active malignancy (other than low-risk well differentiated thyroid cancer); primary or secondary hyperparathyroidism; or documented parathyroid carcinoma within the previous 5 years, acromegaly, or multiple endocrine neoplasia types
•3. Very low or very high blood calcium level (eg, ACSC <1.87 mmol/L [<7.5 mg/dL] or
•=2.97 mmol/L [=11.9 mg/dL]) at the Week -3 screening visit. Results from the central laboratory must be used for this assessment
•4. If the Blood calcium level is above the ULN at the baseline (Week 0) visit, the analysis can be repeated another day as long as the next date is within the visit window for the baseline visit. If the subject does not met exclusion #4 on the repeat measure the subject may be randomized.
•5. Use of prohibited medications, such as loop and thiazide diuretics, phosphate binders (other than calcium carbonate), digoxin, lithium, methotrexate, or systemic corticosteroids, within respective prohibited periods. See Section 5 (Prior and Concomitant Treatment) for a list of prohibited and restricted medications
•6. Participation in any other investigational study in which receipt of investigational drug or device occurred within 6 months before screening for this study. Prior treatment with PTH-like drugs (whether commercially available or through participation in an
•investigational study), including PTH(1-84), PTH(1-34), or other N-terminal fragments or analogs of PTH or PTH-related protein, within 3 months before screening.
•7. Use of other drugs known to influence calcium and bone metabolism, such as calcitonin, fluoride tablets, or cinacalcet hydrochloride, within the prohibited period.
•8. Use of oral bisphosphonates within the previous 6 months or intravenous bisphosphonate
•preparations within the previous 24 months before screening.
•9. Nonhypocalcemic seizure disorder with a history of a seizure within the previous 6 months before screening. Subjects with a history of seizures that occur in the setting of hypocalcemia are allowed.
•10. The subject is at increased baseline risk for osteosarcoma, such as those with Paget’s disease of bone or unexplained elevations of alkaline phosphatase, hereditary disorders predisposing to osteosarcoma, or with a prior history of external beam or implant radiation therapy involving the skeleton.
•11. Any disease or condition that, in the opinion of the investigator, may require treatment or make the subject unlikely to fully complete the study, or any condition that presents undue risk from the investigational product or procedures. For example, illness that is anticipated to be chronic and not transient.
•12. Pregnant or lactating women.
•13. Known or suspected intolerance or hypersensitivity to the investigational product, closely-related compounds, or any of the stated ingredients. Refer to the investigator’s brochure for the list o

Investigators

Sponsor

Shire Human Genetic Therapies, Inc.

Similar Trials

Completed

Phase 3

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients with Type 2 Diabetes post Worsening Heart Failure

NL-OMON50219exicon Pharmaceuticals, Inc.65

Active, not recruiting

Phase 1

Effect of Efpeglenatide on Cardiovascular OutcomesType 2 diabetes mellitusMedDRA version: 21.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disorders

EUCTR2017-002954-35-FIsanofi-aventis recherche & développement5,000

Active, not recruiting

Phase 1

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular RiskType 2 diabetes mellitusChronic kidney diseaseMedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disorders

EUCTR2017-002644-32-NOSANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT16,154

Active, not recruiting

Phase 1

GRAVITI - A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Crohn’s DiseaseModerately to Severely Active Crohn's DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disorders

EUCTR2020-006165-11-DEJanssen-Cilag International NV350

Withdrawn

Phase 2

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple-dose Phase 2 Study to Evaluate the Efficacy and Safety of BMS-986263 in Adults with Compensated Cirrhosis from Nonalcoholic Steatohepatitis (NASH)

NL-OMON53971Bristol-Myers Squibb6